Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Uwe Dorwarth, Bernhard Witzenbichler et al.|The Lancet Respiratory Medicine|2021Cited by 104